Bayer gets FDA priority review for blood cancer drug
May 17, 2017 at 04:15 AM EDT
FRANKFURT, Germany, May 17 (Reuters) - German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.
